In the second quarter of 2026, Leaven Partners assets depreciated by -4.6%. Over the three-year period, the fund is up 59.6% ...
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results